Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial [version 2; peer review: 2 approved, 1 approved with reservations]

Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial [version 2; peer review: 2 approved, 1 approved with reservations]

Introduction: Antimalarial therapeutic efficacy studies are routinely conducted in malaria-endemic countries to assess the effectiveness of antimalarial treatment strategies. Targeted amplicon sequencing (AmpSeq) uniquely identifies and quantifies genetically distinct parasites within an infection....

Full description

Bibliographic Details
Main Authors: Mainga Hamaluba, Juliana Wambua, Arjen M. Dondorp, Jennifer Musyoki, Caroline Ngetsa, Oksana Kharabora, Leonard Ndwiga, Zaydah de Laurent, Kevin Wamae, Kelvin Kimenyi, Gabriel Mwambingu, Peter Kalume, Philip Bejon, Jeffrey Bailey, Rob van der Pluijm, Lynette Ochola-Oyier, Jonathan Juliano, Victor Osoti
Format: Article
Language:English
Published: Wellcome 2022-12-01
Series:Wellcome Open Research
Subjects:
Artemisinin-based combination therapy
pfama1
Pfmdr1
artemisinin resistance
antimalarial resistance
targeted deep sequencing
eng
Online Access:https://wellcomeopenresearch.org/articles/7-95/v2

Internet

https://wellcomeopenresearch.org/articles/7-95/v2

Similar Items